We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00093145
First Posted: October 5, 2004
Last Update Posted: July 17, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Celgene ( Celgene Corporation )
October 4, 2004
October 5, 2004
May 7, 2013
July 17, 2013
July 17, 2013
June 2004
October 2008   (Final data collection date for primary outcome measure)
Percentage of Participants Who Achieved an Objective Confirmed Complete or Partial Overall Response [ Time Frame: Objective response was evaluated every 2 cycles, up to a maximum of 39 cycles (approximately 39 months) ]
Percentage of participants who achieved an objective confirmed complete or partial overall response based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. A complete response (CR) is the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. A partial response (PR) is at least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing, or with the persistence of one or more non-target lesions and/or the maintenance of tumor marker level above the normal limits.
Percentage of patients who achieve an objective confirmed complete or partial target lesion response based on the RECIST response criteria.
Complete list of historical versions of study NCT00093145 on ClinicalTrials.gov Archive Site
  • Percentage of Participants With a Total Response [ Time Frame: Evaluated every 2 cycles, up to a maximum of 39 cycles. ]
    Total response was defined as the percentage of participants with stable disease (SD) for ≥ 16 weeks or complete or partial overall response. Stable disease was defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. Progressive disease is at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
  • Time to Disease Progression [ Time Frame: Assessed every 2 cycles, up to a maximum of 39 cycles. ]
    Time to disease progression was measured from the date of first dose of study drug to the start of disease progression. Patients who did not have disease progression at the end of follow-up were censored at the last known time that the patient was evaluated for progression. Progression is at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion. Time to disease progression was summarized using Kaplan-Meier methods.
  • Duration of Response [ Time Frame: Assessed every 2 cycles, up to a maximum of 39 cycles. ]
    Duration of response was evaluated by measuring progression-free survival for participants with a complete response or partial response. Progression-free survival was defined as the time from the first dose of study drug to the start of progression or patient death (whichever occurred first). Participants who did not have progression or were still alive were censored at the last known time the patient was progression free. Patients that initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progression is at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
  • Overall Patient Survival [ Time Frame: From Day 1 until approximately 44 months. ]
    Overall survival was defined as the time from the day of randomization to patient death (due to any cause), as assessed by post study follow-up on a monthly basis for 3 months and every 3 months. Participants still alive were censored at the last known time that the patient was alive. Patient survival was estimated using Kaplan-Meier methods.
  • Number of Participants With Adverse Events (AEs) [ Time Frame: Day 1 up to 39 cycles ]
    A Treatment-emergent AE was any AE that began or worsened after the start of study drug through 30 days after the last dose of study drug or end of study whichever is later. A treatment related toxicity was one considered by the investigator to be possibly, probably or definitely related to study drug. AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on the following scale: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death. A serious adverse event (SAE) is any untoward medical occurrence at any dose that: is fatal or life-threatening; results in persistent or significant disability or incapacity; requires or prolongs in-patient hospitalization; is a congenital anomaly/birth defect in the offspring of a patient; and conditions not included in the above that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above
  • Percentage of patients with stable disease for 16 weeks
  • Time to Disease Progression
  • duration of response
  • patient survival
Not Provided
Not Provided
 
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
A Phase II Study of Weekly Dose-Dense Nanoparticle Paclitaxel (ABI-007), Carboplatin With Herceptin® As First-Line Therapy of Advanced HER-2 Positive Breast Cancer
This trial will treat patients with advanced breast cancer with a new anti-cancer medicine used in combination with two existing anti-cancer medications: Albumin-bound paclitaxel (ABI-007), Carboplatin and Herceptin. Participants will be given the combination therapy on a weekly basis and may continue on therapy as long as their condition improves and drug toxicity is tolerated.
Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Breast Cancer
  • Drug: Albumin-bound paclitaxel
    Administered by intravenous infusion.
    Other Names:
    • ABI-007
    • ABRAXANE®
  • Drug: Carboplatin
    Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.
    Other Name: Paraplatin®
  • Drug: Herceptin®
    Administered by IV infusion
    Other Name: Trastuzumab
Experimental: Albumin-bound paclitaxel, Carboplatin + Herceptin
Participants received albumin-bound paclitaxel, 100 mg/m^2 weekly every 3 out of 4 weeks, carboplatin at an area under the curve (AUC) = 6 every 4 weeks and Herceptin weekly, 4 mg/kg the first week and 2 mg/kg on all subsequent weeks by intravenous (IV) infusion for up to 6 cycles in the absence of disease progression or intolerable toxicity. Participants could continue treatment with chemotherapy beyond 6 cycles at the discretion of the investigator, but Herceptin therapy was to continue to be administered weekly (2 mg/kg) until intercurrent illness, disease progression, unacceptable toxicity, patient withdrawal or administration of any non-protocol anti-cancer treatment.
Interventions:
  • Drug: Albumin-bound paclitaxel
  • Drug: Carboplatin
  • Drug: Herceptin®
Conlin AK, Seidman AD, Bach A, Lake D, Dickler M, D'Andrea G, Traina T, Danso M, Brufsky AM, Saleh M, Clawson A, Hudis CA. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2010 Aug 1;10(4):281-7. doi: 10.3816/CBC.2010.n.036.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
32
October 2008
October 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Confirmed adenocarcinoma of the breast
  • Tumor shows 3+ overexpression of the human epidermal growth factor receptor 2 (HER-2)/proto-oncogene by immunohistochemistry assay, or is fluorescence in situ hybridization (FISH)+
  • Stage IV disease
  • Measurable disease
  • At least 3 weeks since prior cytotoxic chemotherapy
  • At least 4 weeks since radiotherapy with full recovery
  • At least 4 weeks since major surgery with full recovery
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • At least 18 years old
  • Absolute neutrophil count (ANC) at least 1.5 x 10^9 cells/L
  • Platelets at least 100 x 10^9 cells/L
  • Hemoglobin at least 9 g/dL
  • Aspartame aminotransferase (AST), alanine aminotransferase (ALT) less than 2.5X upper limit normal
  • Alkaline Phosphatase less than 1.5X upper limit normal
  • Creatinine less than 1.5 gm/dL
  • Normal left ventricular ejection fraction
  • Negative pregnancy test
  • Agree to use method to avoid pregnancy
  • Informed Consent is obtained

Exclusion Criteria:

  • Up to one regimen of prior neo-adjuvant or adjuvant chemotherapy is allowed. One year since Taxane and Herceptin treatment.
  • Cumulative life-time dose of doxorubicin is greater than 360 mg/m^2
  • Concurrent immunotherapy or hormonal therapy
  • Parenchymal brain metastases, if present, must be documented to be clinically and radiographically stable for at least 6 months after treatment
  • Serious intercurrent medical or psychiatric illness, including serious active infection
  • History of congestive heart failure
  • History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer
  • Patients who have received an investigational drug within the previous 3 weeks
  • Patient is currently enrolled in another clinical study receiving investigational therapies
  • Pregnant or nursing women
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00093145
CA016
No
Not Provided
Not Provided
Celgene ( Celgene Corporation )
Celgene Corporation
Not Provided
Principal Investigator: Andrew Seidman, MD Memorial Sloan Kettering Cancer Center
Celgene
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP